Patients with mildly reduced liver function can take lenvatinib, but patients whose liver function is severely impaired by the drug need to stop taking lenvatinib. Lenvatinib is mainly used for patients with unresectable hepatocellular carcinoma who have not received systemic treatment in the past. It can inhibit the angiogenesis and immunosuppression in the microenvironment of hepatocellular carcinoma, and also directly inhibit the proliferation of the cancer cells, and it can be used as the first-line drug for patients with unresectable hepatocellular carcinoma. Its common adverse reactions also include hypertension, diarrhea, decreased appetite, hand-foot syndrome, nausea, fatigue, proteinuria and hypothyroidism. Lenvatinib is mainly eliminated through hepatic metabolism, which can lead to hepatotoxic side effects such as elevated blood bilirubin, elevated ghrelin, elevated ghrelin, hypoalbuminemia, and elevated blood alkaline phosphatase, etc. Therefore, when hepatotoxicity occurs, it is necessary to interrupt the administration of the drug, adjust the dosage, or discontinue the drug in accordance with the doctor’s instructions. Lenvatinib is recommended to go to the hospital to check the degree of hepatic function, under the guidance of the doctor.